When: Daily close above 50 SMA at $1,176 with volume confirmation AND MACD line cross above signal (not just histogram)

Then: Deploy Tranche 2

When: Revenue trajectory reaffirming 48% and Foundayo traction

Then: Deploy Tranche 3

When: Defended $1,063 test with RSI sub-30 and positive MACD divergence

Then: Deploy Tranche 3

Reduce proposed entry size; start with 15-20% starter position instead of 50% tranche; hold second tranche for confirmed technical signals; widen stop loss to ~$1,050 and reduce position size accordingly

• PEG of 1.14 is misleading as it doesn't price integration risk, failed Phase 3 readouts, or payer pushback on tirzepatide pricing
• Net debt jumped from $32.7B to $46B in nine months (40% leverage expansion)
• $6.5B Houston facility bet won't be operational until 2030
• $8.7B in acquisitions plus $3.28B in intangibles booked
• 39x trailing P/E with 30x price-to-book is rich by historical pharma standards
• 50 SMA at $1,176 acting as overhead resistance; stock below declining 50 SMA
• 200 SMA sits at $1,064.25; proposed entry at first touch of structural support without confirmed basing pattern
• ATR is $30; $1,105 stop is ~1.4 ATRs which is too tight per standard risk management (should be 2+ ATRs)
• Net debt up $13B in nine months; debt-to-equity at 162%; capex stepping up to $10-12B annual run rate
• Free cash flow yield of just 1.07% on $1T market cap
• 54% operating margin with 900bps expansion over past year reflects favorable conditions that may not persist
• Stock in first stretch of S&P underperformance since 2016; no marginal retail bid to support downside
• Bull case has multiple single points of failure: Foundayo, Novo competition, Inluriyo launch, Houston conviction
• MACD histogram flipped positive but MACD line has not crossed; described as 'early/forming, not confirmed'
• 13% drawdown from recent peak; not a normal 5% pullback in a stable uptrend

→ vs aggressive: PEG of 1.14 is a misleading frame because it doesn't price integration risk from $8.7B acquisitions, a failed Phase 3 readout, or operating margin compression of 300bps if a payer pushes back on tirzepatide pricing

→ vs aggressive: The 13% pullback is not just a 'breather'—the 50 SMA is still declining and acting as overhead resistance, MACD line hasn't crossed (only histogram flipped positive), and the 200 SMA entry at $1,064 is at first touch of support without confirmed basing pattern

→ vs aggressive: The $1,105 stop loss is too tight at ~1.4 ATRs when standard risk management calls for minimum 2 ATRs (~$1,045); the tight stop will either get wicked out or the risk-reward math is fictional

→ vs aggressive: The 54% operating margin giving 'flexibility' assumes margin persists, but 900bps expansion reflects a period with no competitive oral entrants, no payer pushback, and no integration costs

→ vs aggressive: Bull case presents cumulative tailwinds that are actually cumulative single points of failure—one negative data print (CagriSema non-inferiority, Foundayo safety signal, Inluriyo disappointment) reprices the entire narrative

→ vs neutral: The Reddit silence argument cuts both ways: no marginal retail bid means downside is uncapped when institutional flows rotate out, unlike frothy names that get rescued by social media momentum

BUY with phased deployment: 25-30% at $1,064 with $1,105 stop (smaller size) or $1,080 stop (50% position), 30-40% on confirmed breakout above $1,176, 30% reserve for post-Q3 earnings

• PEG of 1.14 is not a slam dunk; LLY carries $46B net debt, $8.7B acquisition, $3.28B intangibles
• Technical setup requires confirmation: 50 SMA still declining, MACD histogram flipped but line has not crossed positive
• Initial 50% tranche at $1,064 is too aggressive before basing pattern confirmation; reduce to 25-30% of target Overweight
• Stop-loss placement is too tight at $1,105 for meaningful size, but $1,050 widens to structural floor; position size must match stop
• 3.9% per-share stop from $1,064 entry implies maximum 25-50% of target allocation under standard 1-2% portfolio risk rules
• 15-20% starter position too small if fundamentals are genuinely compelling; reflects hedge, not conviction
• 2022 pharma drawdown is cherry-picked; current macro is opposite (96% probability of zero rate cuts in 2026, 6% recession risk)
• Lack of retail froth is genuinely neutral, not a one-way risk indicator
• Q3 earnings is the single biggest catalyst; should not be fully positioned into an unknown
• Balance sheet is manageable ($11B annual FCF, 54% operating margins) but margin for error is smaller than 12 months ago

→ vs aggressive: PEG of 1.14 ignores $46B net debt, $8.7B acquisition, $3.28B intangibles, and 16-17% R&D intensity; the multiple assumes everything goes right

→ vs aggressive: 50 SMA still declining and MACD line has not crossed positive; buying at first touch of 200 SMA in a stock that has not established a higher low is a guess, not high probability

→ vs conservative: 15-20% starter position is too small if the setup is compelling; either size to conviction or don't initiate at all

→ vs conservative: Widening stop to $1,050 uses the 200 SMA as invalidation point while simultaneously betting it holds; inconsistent framework

→ vs conservative: 2022 drawdown comparison ignores macro context; current soft-landing backdrop favors high-quality pharma compounders

→ vs conservative: Reddit silence argument is inverted; no retail froth means fundamentals-driven moves, not sentiment distortion